Short Interest in Applied DNA Sciences, Inc. (NASDAQ:APDN) Declines By 5.1%

Applied DNA Sciences, Inc. (NASDAQ:APDN) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 5,030,000 shares, a decline of 5.1% from the December 31st total of 5,300,000 shares. Based on an average daily volume of 6,020,000 shares, the days-to-cover ratio is presently 0.8 days.

Hedge Funds Weigh In On Applied DNA Sciences

An institutional investor recently bought a new position in Applied DNA Sciences stock. Jane Street Group LLC acquired a new position in Applied DNA Sciences, Inc. (NASDAQ:APDN) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 73,396 shares of the technology company’s stock, valued at approximately $48,000. Jane Street Group LLC owned about 0.24% of Applied DNA Sciences at the end of the most recent quarter. Hedge funds and other institutional investors own 22.22% of the company’s stock.

Applied DNA Sciences Stock Down 2.8 %

APDN stock opened at $0.17 on Tuesday. The stock has a 50-day simple moving average of $0.19 and a two-hundred day simple moving average of $0.54. Applied DNA Sciences has a twelve month low of $0.12 and a twelve month high of $14.40. The firm has a market capitalization of $9.39 million, a PE ratio of -0.02 and a beta of 0.37.

Applied DNA Sciences (NASDAQ:APDN) last posted its earnings results on Tuesday, December 17th. The technology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. Applied DNA Sciences had a negative net margin of 203.76% and a negative return on equity of 111.18%. On average, equities research analysts anticipate that Applied DNA Sciences will post -0.87 EPS for the current fiscal year.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.